Actively Recruiting
Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants
Led by Ensho Therapeutics, Inc. · Updated on 2026-02-11
24
Participants Needed
1
Research Sites
17 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to evaluate the pharmacokinetics, safety, and tolerability of NSHO-101 in Healthy Participants.
CONDITIONS
Official Title
Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants (males and females) at least 18 years of age
- Ability to provide written informed consent
- In good heath as determined by medical evaluation
- Willing and able to comply with trial restrictions, procedures, and requirements
You will not qualify if you...
- Known sensitivity to any components of the IMP
- History of relevant drug hypersensitivity
- Presents or has a history of clinically significant diseases
- History of difficulty swallowing tablets or capsules
- Any physical examination findings or medical history that might place the participant at an unacceptable risk for participation in this trial
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Cenexel Anaheim CA
Anaheim, California, United States, 92801
Actively Recruiting
Research Team
B
Bittoo Kanwar, MD, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here